Topic
biotech-finance
2 stories related to this topic, newest first.
finance.yahoo.comfinance1 day agoSourced
enGene Therapeutics Reports Departure of Chief Financial Officer
enGene Therapeutics Inc. disclosed the resignation of its chief financial officer in an 8-K filing with the SEC. The change triggers standard disclosure obligations and requires the company to identify a successor or interim officer in subsequent regulatory filings.
manilatimes.netfinance1 day agoSourced
Avalo Therapeutics Enters Material Agreement and Reports First-Quarter Financial Results
Avalo Therapeutics disclosed entry into a material definitive agreement along with its first-quarter 2026 results of operations in an 8-K filing. The disclosures set contractual and reporting obligations that require the company to meet defined milestones and trigger subsequent S…